2025’s Breakthrough Findings on Urolithin A

Research on Urolithin A continues to be published at a rapid rate, expanding its potential beyond muscle and skin health into immune ageing, recovery, mental health, and cardiovascular domains. Several high-quality clinical trials were completed in 2025, and preclinical work is opening new frontiers.

Backed by more than 15 years of research, Urolithin A has become one of the most intensively studied longevity molecules.

As we close out 2025, the momentum is clear. Let’s explore the key discoveries of 2025, followed by a forward look to 2026.

New Clinical Data

Timeline is dedicated to producing gold-standard research published in some of the highest impact peer-reviewed journals in the field. Here are some key trials from 2025.

MitoImmune Trial: A Breakthrough Clinical Study

One of the most significant clinical milestones of 2025 comes from the publication of the MitoImmune study in Nature Aging.

Conducted in collaboration with the Buck Institute and the Georg-Speyer-Haus Institute, this double-blind, placebo-controlled trial evaluated whether 1,000 mg of Mitopure® daily could sustain immune fitness in healthy adults aged 45–70.

Over 28 days, researchers assessed several hallmarks of immune aging to determine whether targeting mitochondrial health could have a positive impact. The findings demonstrate that Urolithin A may support a more youthful, adaptable immune system by improving both cellular energetics and functional activity.

Key findings include:

• Increased naïve CD8+ T-cell levels and reduced exhaustion markers, indicating improved immune surveillance.
• A shift toward cleaner energy metabolism in immune cells.
• Evidence of mitochondrial biogenesis, supporting renewal of healthy mitochondria.
• Enhanced immune-cell activity ex vivo, with improved clearance of E. coli particles.
• Strong safety and tolerability with no serious adverse events reported.

This trial paves the way for researchers to explore a nutritional strategy to support immune fitness via mitochondrial pathways.

ENDURO Trial

The Enduro Trial, published in Sports Medicine, evaluated Mitopure’s effect on endurance performance and mitochondrial health in elite athletes over 4 weeks.

This randomized, double-blind, placebo-controlled trial of 42 highly-trained male distance runners monitored how supplementation with 1000 mg/day impacted recovery and mitochondrial protein signatures.

Participants who took 1,000 mg/day of Mitopure showed:^[1]

• Lower levels of exercise-induced muscle strain as measured by creatine kinase levels
• Improved rates of perceived exertion during training sessions
• Elevation in protein levels related to mitochondrial function

These results indicate Urolithin A may enhance adaptation and recovery in elite endurance contexts, even if direct performance gains remain to be confirmed.

Elite Soccer Player Study

In a pilot randomized controlled trial involving academy soccer players, Urolithin A supplementation was evaluated for its impact on performance and antioxidant status during preseason training.

After 6 weeks of 1,000 mg/day Mitopure, athletes experienced:^[2]

• Statistically significant improvement in aerobic performance
• Improvements in lower limb performance

This study suggests that 1000mg of Urolithin A could improve measures of both aerobic endurance and lower-limb performance in an already-fit population.

Promising Pre-Clinical Data

Early research into mental health and heart health also shows promising results. Here are some of the preclinical highlights from 2025.

Urolithin A Reverses Anxiety-Like Behavior in Rats

A preclinical study revealed that Urolithin A supplementation reduced anxiety-like behavior in rat models.

Rats subjected to anxiety-induction protocols received Urolithin A supplementation and showed significant behavioural, neurochemical, and mitochondrial-function improvements.

Researchers found that Urolithin A:

• Reversed high-anxiety behaviors
• Promoted brain mitochondrial repair
• Restored healthy neuronal structure
• Restored a key mitochondrial protein^[3]

While these results are early-stage, they expand Urolithin A’s relevance into brain health, a promising direction for future clinical research.

Urolithin A has not been studied for these outcomes in human clinical trials.

Urolithin A and Cardiovascular Health

A recent preclinical study published in iScience, examined the impact of Urolithin A in several animal models.

In animal models of heart failure, Urolithin A supplementation led to:

• Improved ejection fraction, indicating more effective blood pumping
• Enhanced diastolic function, reflecting better relaxation between heartbeats
• Reduced pathological chamber enlargement
• Correction of mitochondrial gene-expression defects associated with heart failure

In healthy older animals, Urolithin A supplementation resulted in:

• Better diastolic and systolic function
• Preserved ejection fraction
• Retained skeletal-muscle strength compared to untreated aging animals
• Reversal of age-related mitochondrial structural abnormalities
• Improved markers of mitophagy in cardiac tissue

In humans, daily Urolithin A for 4 months was associated with:

• Reduced plasma ceramides, an emerging lipid biomarker for cardiovascular risk

These findings suggest that Urolithin A's mitophagy-enhancing and mitochondrial resilience effects extend into heart tissue in animal models. This paves the way for studying Urolithin A’s potential to target cardiovascular aging in humans.

Urolithin A has not been studied for these outcomes in human clinical trials.

Looking Ahead to 2026

2025 marked another major milestone year for Urolithin A research, with clinical and preclinical findings deepening our understanding of its broad benefits.

In 2026, several highly anticipated human trials are expected to report results, including those examining:

• Brain health: With 650 participants, this study will be the largest clinical study ever conducted on Mitopure to date
• Immune health: Building on the success of the MitoImmune trial, researchers will be studying Mitopure’s potential as a nutritional supplement to complement immunotherapy in cancer patients.

As aging science accelerates globally, Mitopure remains the only clinically tested form of Urolithin A.

Mitopure Softgels

4.5 · 3713 reviews

The simplest form of Mitopure

Buy now